AdAlta is extending Phase I clinical studies for its lead i-body® enabled candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. Preparation for Phase II clinical studies is also underway. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.
The Company is also entering collaborative partnerships to advance the development of its i-body® platform. It has a collaboration with Carina Biotech to codevelop precision engineered, i-body® enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immunooncology drugs, a program now in preclinical development.
- Forums
- ASX - By Stock
- Ann: AdAlta presenting at ASX Gems conference
AdAlta is extending Phase I clinical studies for its lead...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1AD (ASX) to my watchlist
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.29M |
Open | High | Low | Value | Volume |
2.4¢ | 2.4¢ | 2.2¢ | $18.97K | 795.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 562562 | 2.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.6¢ | 220037 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 562562 | 0.022 |
2 | 1047615 | 0.021 |
2 | 526797 | 0.020 |
2 | 1028500 | 0.019 |
3 | 338053 | 0.018 |
Price($) | Vol. | No. |
---|---|---|
0.026 | 220037 | 2 |
0.027 | 200000 | 1 |
0.028 | 104333 | 2 |
0.029 | 3041 | 1 |
0.030 | 17697 | 1 |
Last trade - 15.51pm 17/07/2024 (20 minute delay) ? |
Featured News
1AD (ASX) Chart |